Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215650) titled 'Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Candid Therapeutics
Condition:
Generalized Myasthenia Gravis
Intervention:
Drug: Cizutamig
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 2025
Target Sample Size: 44
To know more, visit https://clinicaltrials.gov/study/NCT07215650
Published by HT Digital Content Services with permission from Health Daily Digest....